Ascension saw its operating margin squeezed during the latter half of 2017 as a result of slumping admissions and revenue lost from divestitures. At the same time, the system has managed to draw more revenue per discharge.Original Article
You may also like
Ninth Circuit Upholds FDA’s Authority to Regulate...
Skinny-Label Lives to See Another Day
Bring Out Your Meds! Bring Out Your Meds!
Homeopathic Industry Group Wants Court to Exclude It...
A Reversal on Sequencing? Proposed Legislation Would...
FDA Guidance Outlines a Framework for the Evaluation...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.